CinCor Pharma, Inc. Common Stock
CINC
CINC was delisted on the 23rd of February, 2023.
86 hedge funds and large institutions have $1.21B invested in CinCor Pharma, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 38 increasing their positions, 12 reducing their positions, and 5 closing their positions.
580% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 5
217% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 12
104% more capital invested
Capital invested by funds: $596M → $1.21B (+$617M)
51% more funds holding
Funds holding: 57 → 86 (+29)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
83% less call options, than puts
Call options by funds: $617K | Put options by funds: $3.69M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$27.9M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$22.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$21.6M |
| 4 |
5VM
5AM Venture Management
San Francisco,
California
|
+$17M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$16.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCV
Sands Capital Ventures
Arlington,
Virginia
|
-$17.9M |
| 2 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$11.5M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$10.4M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$9.38M |
| 5 |
VP
venBio Partners
San Francisco,
California
|
-$7.99M |
CINC Hedge Fund Activity: Q3 2022 in Review
86 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q3 2022, worth a combined $1.21B — up 104% from $596M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CINC positions and 5 closed out — a net gain of 29 holders — while 38 added to existing stakes and 12 trimmed.
The largest buyer was Perceptive Advisors, adding an estimated $27.9M. The largest seller was Sands Capital Ventures, exiting entirely with an estimated $17.9M sold.
- 86 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q3 2022, up from 57 in Q2 2022.
- Funds reported $1.21B of CinCor Pharma, Inc. Common Stock stock for Q3 2022, up 104% quarter-over-quarter.
- 34 funds opened new CinCor Pharma, Inc. Common Stock positions in Q3 2022 and 5 closed out, a net change of +29 holders.
- The largest CinCor Pharma, Inc. Common Stock buyer in Q3 2022 was Perceptive Advisors, an estimated $27.9M added.
- The largest CinCor Pharma, Inc. Common Stock seller in Q3 2022 was Sands Capital Ventures, an estimated $17.9M sold.
Based on aggregated 13F filings for Q3 2022.